MX357193B - Moleculas de union anti-alfa sinucleina. - Google Patents

Moleculas de union anti-alfa sinucleina.

Info

Publication number
MX357193B
MX357193B MX2014000054A MX2014000054A MX357193B MX 357193 B MX357193 B MX 357193B MX 2014000054 A MX2014000054 A MX 2014000054A MX 2014000054 A MX2014000054 A MX 2014000054A MX 357193 B MX357193 B MX 357193B
Authority
MX
Mexico
Prior art keywords
binding molecules
synuclein
alpha synuclein
alpha
synuclein binding
Prior art date
Application number
MX2014000054A
Other languages
English (en)
Other versions
MX2014000054A (es
Inventor
Weihofen Andreas
Grimm Jan
Hock Christoph
Nitsch Roger
Su Lihe
Weinreb Paul
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of MX2014000054A publication Critical patent/MX2014000054A/es
Publication of MX357193B publication Critical patent/MX357193B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Abstract

La presente invención se refiere a moléculas de unión específicas de a-sinucleína anti-humano, por ejemplo, anticuerpos o fragmentos de unión de antibeno, variantes o derivados de los mismos, como métodos relacionados con los mismos. Además se proporcionan moléculas de unión de a-sinucleína anti-humana que unen a epítopos N terminales y C terminales específicos. Las moléculas de unión descritas en la presente pueden usarse en las composiciones farmacéuticas y de diagnóstico para la inmunoterapia y diagnóstico de a-sinucleína dirigida, respectivamente.
MX2014000054A 2011-06-23 2012-06-22 Moleculas de union anti-alfa sinucleina. MX357193B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161500580P 2011-06-23 2011-06-23
PCT/US2012/043701 WO2012177972A1 (en) 2011-06-23 2012-06-22 Anti-alpha synuclein binding molecules

Publications (2)

Publication Number Publication Date
MX2014000054A MX2014000054A (es) 2014-05-01
MX357193B true MX357193B (es) 2018-06-29

Family

ID=47422964

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000054A MX357193B (es) 2011-06-23 2012-06-22 Moleculas de union anti-alfa sinucleina.

Country Status (23)

Country Link
US (3) US9580493B2 (es)
EP (1) EP2723379B1 (es)
JP (2) JP2014528695A (es)
KR (1) KR101976887B1 (es)
CN (1) CN103796679B (es)
AU (1) AU2012272790B2 (es)
BR (1) BR112013033258B1 (es)
CA (1) CA2839563C (es)
CY (1) CY1121392T1 (es)
DK (1) DK2723379T3 (es)
EA (1) EA030777B9 (es)
ES (1) ES2699801T3 (es)
HR (1) HRP20181553T1 (es)
HU (1) HUE041391T2 (es)
IL (1) IL230028B (es)
LT (1) LT2723379T (es)
MX (1) MX357193B (es)
PL (1) PL2723379T3 (es)
PT (1) PT2723379T (es)
SI (1) SI2723379T1 (es)
TR (1) TR201815563T4 (es)
WO (1) WO2012177972A1 (es)
ZA (1) ZA201309623B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2949666T1 (sl) 2008-12-19 2019-03-29 Biogen International Neuroscience Gmbh Človeška anti alfa-sinukleinska protitelesa
CA2839563C (en) 2011-06-23 2019-10-29 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
EP2970378B1 (en) 2013-03-15 2021-05-26 Biogen MA Inc. Hydrophobic interaction protein chromatography under no-salt conditions
US10214592B2 (en) 2014-08-22 2019-02-26 Nitto Boseki Co., Ltd. Protein assay method specific to TRACP-5b (tartrate resistant acid phosphatase 5b)
WO2016061389A2 (en) 2014-10-16 2016-04-21 Genentech, Inc. Anti-alpha-synuclein antibodies and methods of use
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
PL3430397T3 (pl) 2016-03-14 2022-04-04 Biogen International Neuroscience Gmbh Oznaczenie fagocytozy zależnej od przeciwciał do wiarygodnych pomiarów wychwytu zagregowanych białek
LT3463435T (lt) 2016-06-02 2021-12-27 Medimmune Limited Antikūnai prieš alfa-sinukleiną ir jų panaudojimai
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
KR102593669B1 (ko) * 2016-11-15 2023-10-25 하. 룬드벡 아크티에셀스카브 시누클레인병증의 치료를 위한 제제, 용도 및 방법
EP3562840A1 (en) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
MA47019A (fr) 2016-12-16 2021-04-21 H Lundbeck As Agents, utilisations et procédés
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
JP2018109560A (ja) 2017-01-04 2018-07-12 オムロンオートモーティブエレクトロニクス株式会社 走査式距離測定装置
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
JOP20190227A1 (ar) * 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
WO2018237338A1 (en) * 2017-06-23 2018-12-27 Denali Therapeutics Inc. ANTI-ALPHA-SYNCUCIN ANTIBODIES AND METHODS OF USE
WO2019023809A1 (en) 2017-08-02 2019-02-07 Stressmarq Biosciences Inc. ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEINE
WO2019040617A1 (en) * 2017-08-23 2019-02-28 The Trustees Of The University Of Pennsylvania MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHODS USING SAME
CA3076313A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
MX2020004674A (es) * 2017-11-17 2020-08-13 Abl Bio Inc Anticuerpos contra alfa-sinucleina y usos de los mismos.
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
CN112839710A (zh) 2018-08-09 2021-05-25 霍夫曼-拉罗奇有限公司 帕金森氏病的确定
MA54070A (fr) 2018-10-29 2021-09-08 Biogen Ma Inc Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
CN113968910A (zh) * 2019-07-11 2022-01-25 武汉友芝友生物制药有限公司 四价对称双特异性抗体
NL2025332B1 (en) * 2020-04-10 2021-10-26 Syngle Therapeutics B V Novel alpha-synuclein binding antibodies, or antigen binding portions thereof.
MX2022013173A (es) 2020-04-24 2022-11-30 Hoffmann La Roche Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados.
AU2021298222A1 (en) 2020-06-26 2022-12-15 Bioarctic Ab α-synuclein protofibril-binding antibodies
CN112920274A (zh) * 2021-03-17 2021-06-08 江苏贝格尔生物医药有限公司 一种检测alpha-synuclein蛋白的鼠单克隆抗体及其应用
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
CN117106081A (zh) * 2023-09-28 2023-11-24 北京凯祥弘康生物科技有限公司 一种抗nfl蛋白的捕获抗体

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
DE68921982T4 (de) 1988-06-14 1996-04-25 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
ATE236987T1 (de) 1992-11-13 2003-04-15 Idec Pharma Corp Konsensus-kozak-sequenzen zur säugetier- exprimierung
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
AU721898B2 (en) 1994-11-18 2000-07-20 Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
RO120148B1 (ro) 1997-03-14 2005-09-30 Idec Pharmaceuticals Corporation Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
ATE402717T1 (de) 1997-04-09 2008-08-15 Intellect Neurosciences Inc Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
US6703015B1 (en) 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
WO1999050300A1 (en) 1998-03-30 1999-10-07 The Trustees Of The University Of Pennsylvania Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CA2274414A1 (en) 1999-06-11 2000-12-11 Universite Laval Dietary fish protein for use in restoring normal insulin function insulin-resistant individuals
EP1180938B1 (en) 1999-09-03 2010-03-24 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents, compositions and methods utilizing the same useful in treating or preventing alzheimer disease
US6187309B1 (en) 1999-09-14 2001-02-13 Milkaus Laboratory, Inc. Method for treatment of symptoms of central nervous system disorders
US6436401B1 (en) 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US6713058B2 (en) 1999-09-14 2004-03-30 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
ATE446366T1 (de) * 2000-06-22 2009-11-15 Genentech Inc Agonistische monoklonale antikörper gegen trkc
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
CN1306272C (zh) 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
WO2002060955A2 (en) 2001-01-29 2002-08-08 Idec Pharmaceuticals Corporation Modified antibodies and methods of use
ITPV20010007U1 (it) 2001-07-19 2003-01-19 Maruscia Food Specialties Comp Contenitore per profilattico nuovo e usato
DK1944040T3 (da) 2001-08-17 2012-10-29 Univ Washington Analysefremgangsmåde for Alzheimers sygdom
US7414111B2 (en) * 2001-09-19 2008-08-19 Alexion Pharmaceuticals, Inc. Engineered templates and their use in single primer amplification
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20110200609A1 (en) 2002-09-12 2011-08-18 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
WO2008103472A2 (en) 2007-02-23 2008-08-28 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
US20060235207A1 (en) 2002-11-22 2006-10-19 Chugai Seiyaku Kabushiki Kaisha Antibodies against lesion tissue
AU2003276107A1 (en) 2003-04-24 2004-11-19 Universitat Zurich Method of monitoring immunotherapy
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2005018424A2 (en) 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
EA009872B1 (ru) 2004-02-23 2008-04-28 Эли Лилли Энд Компани АНТИ-Aβ АНТИТЕЛА
WO2005105998A1 (ja) 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
WO2005120571A2 (en) 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
WO2006050041A2 (en) 2004-10-28 2006-05-11 Ramot At Tel Aviv University Ltd. Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis
PE20061401A1 (es) 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
AU2006222193B2 (en) 2005-03-05 2011-11-17 AbbVie Deutschland GmbH & Co. KG Screening method, process for purifying of non-diffusible A-beta oligomers, selective antibodies against said non-diffusible A-beta oligomers and a process for manufacturing of said antibodies
JP2006265189A (ja) 2005-03-24 2006-10-05 Kyoto Univ βアミロイドペプチド、及びそれを用いたアルツハイマー病治療薬又は予防薬のスクリーニング方法
ES2318918B1 (es) 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
WO2006116192A2 (en) * 2005-04-21 2006-11-02 Medarex, Inc. Irta-1 antibodies and their uses
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US20080300204A1 (en) 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
WO2007021255A1 (en) 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
AU2006347287A1 (en) 2005-11-14 2008-02-21 The Trustees Of Columbia University In The City Of New York Imaging correlates of neurogenesis with MRI
CA2630964A1 (en) 2005-11-22 2007-05-31 The Trustees Of The University Of Pennsylvania Antibody treatment of alzheimer's and related diseases
WO2007064917A2 (en) 2005-11-30 2007-06-07 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
RU2015111675A (ru) 2005-12-12 2015-08-10 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN103408661B (zh) 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
MX2009009926A (es) 2007-03-13 2010-03-15 Univ Zuerich Anticuerpo tumor-especifico humano monoclonal.
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
RU2523894C2 (ru) 2007-04-18 2014-07-27 Янссен Альцгеймер Иммунотерапи Предупреждение и лечение церебральной амилоидной ангиопатии
CN101778867A (zh) * 2007-06-08 2010-07-14 地中海大学 用于治疗胰腺肿瘤的组合物和方法
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
WO2009027105A2 (en) 2007-08-31 2009-03-05 Neurimmune Therapeutics Ag Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
EP2185592B1 (en) 2007-09-13 2013-01-23 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
MX2010003380A (es) 2007-09-26 2010-10-15 U3 Pharma Gmbh Proteinas de union a antigeno de factor de crecimiento tipo factor de crecimiento epidermico de union a heparina.
CA2702880A1 (en) 2007-10-19 2009-04-23 Immunas Pharma, Inc. Antibody capable of specifically binding to a beta oligomer, and use thereof
GB0720912D0 (en) 2007-10-25 2007-12-05 Univ Cardiff Monoclonal Anitbody for APP
EP2205633A1 (en) 2007-10-29 2010-07-14 Innogenetics N.V. New antibodies specific of the -amyloid peptides and their uses as diagnostic agents or drugs
ME01026B (me) 2007-11-16 2012-10-20 Univ Rockefeller Antitijela specifična za protofibrilni oblik beta-amiloid proteina
US8414893B2 (en) * 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
EP2282758B1 (en) 2008-04-29 2018-11-21 BioArctic AB Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
WO2010004434A2 (en) 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
JP2012502649A (ja) * 2008-09-19 2012-02-02 メディミューン，エルエルシー Ｃｄ１０５を対象とする標的結合剤およびその使用
ES2543987T3 (es) 2008-11-13 2015-08-26 Modgene, Llc Reducción de la carga de amiloide beta en tejido no cerebral
SI2949666T1 (sl) 2008-12-19 2019-03-29 Biogen International Neuroscience Gmbh Človeška anti alfa-sinukleinska protitelesa
JP5015984B2 (ja) * 2009-03-18 2012-09-05 株式会社コナミデジタルエンタテインメント ゲームサーバ、ゲームシステム、ゲーム装置、巡回地点更新方法、および、プログラム
US20100256596A1 (en) 2009-04-07 2010-10-07 Cabochon Aesthetics, Inc. Fiber growth promoting implants for reducing the appearance of cellulite
ES2641612T3 (es) 2009-04-17 2017-11-10 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos
US8613924B2 (en) 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
EP2462161B1 (en) 2009-08-06 2017-03-08 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US8378061B2 (en) 2009-09-02 2013-02-19 E.I. Du Pont De Nemours And Company Polyester films with improved oil repellency
CA2839563C (en) 2011-06-23 2019-10-29 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules
JP6263473B2 (ja) 2011-11-02 2018-01-31 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー 脳における高レベルのα−シヌクレインを診断するための抗α−シヌクレイン抗体の使用
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.

Also Published As

Publication number Publication date
ES2699801T3 (es) 2019-02-12
ZA201309623B (en) 2014-08-27
WO2012177972A1 (en) 2012-12-27
MX2014000054A (es) 2014-05-01
US9975947B2 (en) 2018-05-22
PT2723379T (pt) 2018-11-14
HRP20181553T1 (hr) 2018-11-30
JP2014528695A (ja) 2014-10-30
BR112013033258B1 (pt) 2022-09-20
US20170233463A1 (en) 2017-08-17
TR201815563T4 (tr) 2018-11-21
BR112013033258A8 (pt) 2018-04-03
JP6302517B2 (ja) 2018-03-28
DK2723379T3 (en) 2018-10-15
CA2839563C (en) 2019-10-29
IL230028B (en) 2018-06-28
KR20140053974A (ko) 2014-05-08
PL2723379T3 (pl) 2019-05-31
CN103796679B (zh) 2016-10-19
EA201391761A1 (ru) 2014-09-30
EP2723379B1 (en) 2018-09-12
EP2723379A4 (en) 2015-03-04
HUE041391T2 (hu) 2019-05-28
CA2839563A1 (en) 2012-12-27
BR112013033258A2 (pt) 2017-03-01
KR101976887B1 (ko) 2019-05-09
US10301381B2 (en) 2019-05-28
EA030777B9 (ru) 2019-02-28
US20180355027A1 (en) 2018-12-13
EA030777B1 (ru) 2018-09-28
AU2012272790B2 (en) 2016-10-06
US20140369940A1 (en) 2014-12-18
CN103796679A (zh) 2014-05-14
JP2017000160A (ja) 2017-01-05
LT2723379T (lt) 2018-10-25
US9580493B2 (en) 2017-02-28
CY1121392T1 (el) 2020-05-29
AU2012272790A1 (en) 2013-05-09
SI2723379T1 (sl) 2019-03-29
NZ618914A (en) 2015-12-24
EP2723379A1 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
MX357193B (es) Moleculas de union anti-alfa sinucleina.
PH12021550083A1 (en) Human anti-tau antibodies
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
MX340295B (es) Anticuerpos monoclonales anti-c-met.
IN2014CN03936A (es)
MX362039B (es) Anticuerpos anti-il-23.
MY195289A (en) Anti IL-36R Antibodies
TN2014000120A1 (en) Cd27l antigen binding proteins
MX345092B (es) Anticuerpos anti-tau humanos,.
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
SG184310A1 (en) Antibodies that bind human cd27 and uses thereof
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
MX338754B (es) Anticuerpos humanos contra el factor tisular.
PH12014502406B1 (en) Anti-il-23p19 antibodies
MX2013007067A (es) Anticuerpos anti-il-18 y sus usos.
MX365387B (es) Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos.
AR124605A2 (es) Anticuerpos anti-il-36r
TN2013000186A1 (en) Anti-il-23 antibodies

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: WEATHERFORD TECHNOLOGY HOLDINGS, LLC

FG Grant or registration